Advances in Understanding and Management of Myeloproliferative Neoplasms
Alessandro M. Vannucchi, Paola Guglielmelli and Ayalew Tefferi
CA Cancer J Clin 2009;59:171-191; originally published online Apr 15, 2009;
DOI: 10.3322/caac.20009

This information is current as of May 6, 2009

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://caonline.amcancersoc.org/cgi/content/full/59/3/171

To subscribe to the print issue of CA: A Cancer Journal for Clinicians, go to (US individuals only): http://caonline.amcancersoc.org/subscriptions/
Advances in Understanding and Management of Myeloproliferative Neoplasms

Alessandro M. Vannucchi, MD1; Paola Guglielmelli, MD2; Ayalew Tefferi, MD3

Abstract

According to the 2008 World Health Organization classification system for hematologic malignancies, the myeloproliferative neoplasms (MPN) include chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, mastocytosis, chronic eosinophilic leukemia—not otherwise specified, chronic neutrophilic leukemia, and “MPN, unclassifiable.” All of these clinicopathologic entities are characterized by stem cell-derived clonal myeloproliferation, and their phenotypic diversity is ascribed to the occurrence of distinct oncogenic events. In the last 4 years, new JAK2 and MPL mutations have been added to previously described ABL and KIT mutations as molecular markers of disease in MPN. These discoveries have markedly simplified the approach to clinical diagnosis and have also provided molecular targets for the development of small-molecule drugs. In the current article, the authors provide a clinically oriented overview of MPNs in terms of their molecular pathogenesis, classification, diagnosis, and management. CA Cancer J Clin 2009;59:171-191. ©2009 American Cancer Society, Inc.

Introduction

In 1951, William Dameshek1 introduced the term "myeloproliferative disorders (MPD)" to encompass polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF),2 chronic myelogenous leukemia (CML), and Di Guglielmo’s syndrome (erythroleukemia). His proposal was based on similarities in the clinical phenotype of these disorders and on the hypothesis that a generalized proliferation of bone marrow cells, due to some unknown stimuli, was the underlying cause. The association of the Philadelphia (Ph1)-chromosome with CML in 1960,3 and the subsequent recognition of erythroleukemia as a variant of acute myeloid leukemia (AML), distinguished the other three disorders as “classic” Ph1-negative MPD.4

The first systematic attempt to classify MPD and MPD-like clinicopathologic entities was undertaken by the World Health Organization (WHO) committee for the classification of hematologic malignancies.5 According to the 2001 WHO classification system, CML, PV, ET, and PMF were included under the category of “chronic myeloproliferative diseases” (CMPD). The CMPD category also included other “nonclassic” MPD-like disorders such as chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia/hypereosinophilic syndrome (CEL/HES), and “unclassified CMPD.” The identification of BCR-ABL as a CML-specific genetic event, in the context of CMPD, has facilitated accurate molecular diagnosis and effective targeted therapy. The lack of...
knowledge, until recently, on specific genetic defects in the other BCR-ABL-negative classic CMPD necessitated that diagnosis rest on a combination of bone marrow histology and a few clinical and laboratory findings to distinguish clonal from reactive myeloproliferation and one CMPD from another.6

The last 4 years have witnessed fundamental advances in understanding the molecular pathogenesis of classic BCR-ABL-negative CMPD, capped by the discovery of specific molecular abnormalities associated with PV, ET, and PMF.7 As a result, WHO diagnostic criteria have been revised,8 and the term “CMPD” has been changed to “myeloproliferative neoplasms (MPN).”8 It is hoped that newly discovered mutations will also facilitate development of targeted therapy. At the same time, large clinical studies continue to provide practically useful clinical information.

The current review has two main objectives. The first is to provide a general overview of MPN including their molecular pathogenesis and updated WHO classification. The second objective is to describe in more detail the criteria for diagnosis, risk stratification, and management of patients with the classic BCR-ABL-negative MPN including PV, ET, and PMF.

TABLE 1. Recurrent Molecular Abnormalities Associated with Myeloproliferative Neoplasms

| GENETIC ABNORMALITY | DISEASE | FREQUENCY |
|---------------------|---------|-----------|
| BCR-ABL             | Chronic myelogenous leukemia | ≥99% |
| JAK2V617F           | Polycythemia vera          | >95% |
|                     | Essential thrombocytopenia  | ≥60% |
|                     | Primary myelofibrosis       | ≥60% |
|                     | MPN, unclassifiable        | ≥20% |
|                     | Refractory anemia with sideroblasts and thrombocytosis (RARS-T) | ≥50% |
| JAK2 exon 12        | Polycythemia vera          | ≥2%  |
| MPLW515L/K*         | Primary myelofibrosis      | ≥8%  |
|                     | Essential thrombocytopenia  | ≥8%† |
| Involving PDGFRα     | Myeloid neoplasms with eosinophilia | Unknown |
|                     | Mast cell disease          | Unknown |
| Involving PDGFRβ     | Myeloid neoplasms with eosinophilia | Unknown |
|                     | Mast cell disease          | Unknown |
| Involving FGFR1      | Myeloid neoplasms with eosinophilia | Unknown |
|                     | Mast cell disease          | Unknown |
| Involving KIT (D816V as the most frequent) | Mast cell disease | Unknown |

MPN indicates myeloproliferative neoplasm.
*Other infrequent mutations, such as W515A or S505N, have been reported.
†Calculated on JAK2V617F-negative patients.

In the following 2 years, additional mutations in JAK216 and MPL17,18 were reported (Table 1). These different mutant alleles all result in a gain of function due to the constitutive activation of tyrosine kinase-dependent cellular signaling pathways, particularly of the JAK-STAT pathway.19,20 Overall, this would suggest that mutated kinases represent a common pathogenetic mechanism in these disorders and that, as exemplified by the efficacy of the tyrosine kinase inhibitor imatinib in CML, they could represent valid targets for therapy.21,22

Members of the Janus kinase family (JAK1, JAK2, JAK3, and tyrosine kinase 2-Tyk2) are named after the Roman god with two faces, meaning ending and beginning, because they contain two symmetrical kinase-like domains: the C-terminal JAK homology 1 (JH1) domain possesses tyrosine kinase function, whereas the immediately adjacent JH2 domain is enzymatically inactive, but it is credited with negatively regulating the activity of JH1.23,24 Ordinarily, JAKs are associated in an inactive state to the cytoplasmic tail of type 1 or type 2 cytokine receptors (eg, erythropoietin receptor, EpoR; thrombopoietin receptor, MPL; granulocyte colony-stimulating factor receptor, G-CSFR; and interferon-gamma receptor,
to name a few). After the engagement of the receptor by corresponding ligand, JAK undergoes a conformational change and becomes activated via phosphorylation of key tyrosine residues. In turn, phosphorylated JAKs mediate phosphorylation of tyrosine residues of the cytoplasmic domain of the receptors and create a docking site for the recruitment of several proteins, ultimately leading to activation of the signal transducer and activator of transcription (STAT), the mitogen-activated protein (MAP) kinase, and the phosphatidylinositol 3-kinase-AKT (PI3K-AKT) pathways25 (Fig. 1A). Activated STATs dimerize and translocate to the nucleus where they regulate transcription after binding to specific consensus sequences in the promoter regions of several target genes (Fig. 1A). The entire process is tightly controlled at multiple levels by protein tyrosine phosphatases, suppressors of cytokine signaling (SOCS), and protein inhibitors of activated STAT.26-29 JAK2, and possibly other JAKs, is also involved in the expression of cognate receptors EPOR and MPL at the cell surface by acting as a chaperon and protein stabilizer.30,31

The JAK2V617F mutation is a somatically acquired G to T nucleotide shift at position 1849 in exon 14 that results in a valine to phenylalanine substitution at codon 617; the mutation is located in the JH2 pseudo-kinase domain and is believed to result in the loss of auto-inhibitory control of JAK2 (Fig. 1B). As a consequence, mutated JAK2 is in a constitutively phosphorylated state, independent from the binding of ligand to its receptor; in fact, when the mutation is introduced into cytokine-dependent cell lines it results in a cytokine-independent growth of the cells and their hypersensitivity to cytokines,13,14 mimicking the in vitro growth pattern of hematopoietic progenitors from MPN patients. In particular, the gain of function of mutated JAK2 provides a mechanistic explanation for the phenomenon of endogenous erythroid colony formation (EEC),33,34 i.e., the capacity of erythroid progenitors to spontaneously produce megablast colonies in vitro in the absence of added erythropoietin, a hallmark of PV and other classic MPNs. Furthermore, transplantation of JAK2V617F mutated cells induced a PV-like phenotype in recipient mice,13,35-38 accompanied by leukocytosis of a different extent and eventually followed by changes suggestive of myelofibrotic transformation.35-38 More recently, by manipulating expression levels of the V617F allele, mice with an ET-like phenotype were also generated in the presence of low levels of mutated JAK2.39 Over-
all, these models indicated that the *JAK2*V617F mutation is sufficient to induce a MPN-like phenotype in mice and suggested that the level of mutated allele may influence disease phenotype.\(^40\)

Mutational frequency of *JAK2*V617F is estimated to be more than 95% in PV, 60% in ET or PMF, 40% to 50% in refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T),\(^41\) whereas it is very rare in AML or MDS.\(^42\)-\(^45\) In most patients with PV or PMF, as opposed to a minority of those with ET, the mutation is harbored in a homozygous state, which is accomplished by mitotic recombination.\(^12\)-\(^15\)

In general, the highest V617F allele burden, that is the level of mutated allele relative to normal allele in a cell suspension such as granulocytes, is found in patients with PV followed by PMF and ET\(^46\),\(^47\); however, such variability in the allele burden does not represent a sufficient criterion for distinguishing among different clinical entities, nor does it satisfactorily help to explain the apparent paradox of “one mutant allele-different clinical phenotypes.” In fact, how a single V617F mutation can be the basis of different clinical disorders, as in the classic MPN, is still unclear. Interestingly, single nucleotide polymorphisms (SNPs) in *JAK2* have been associated preferentially with the diagnosis of PV,\(^48\) supporting the contribution of inherited host genetic characteristics to MPN phenotypic variability. Regardless, there is evidence to suggest that *JAK2*V617F may not be the initial clonogenic event in MPN and that a “pre-*JAK2*” mutated cell may exist.\(^49\),\(^50\) In support of this is also a finding that leukemic blasts in patients who evolve to AML from a pre-existing *JAK2*V617F-positive MPN are often negative for the *JAK2*V617F mutation.\(^51\),\(^52\) Conversely, *JAK2*V617F, or other *JAK2* mutations, are likely a necessary component of the PV phenotype because they are detected in virtually all patients with the disease\(^53\) and are sufficient to reproduce the phenotype in mice. In summary, *JAK2*V617F mutation is integral to the classic MPN, but its exact hierarchical position in pathogenesis and its role in phenotypic variability remain to be clarified. After all, one could conclude that PV, ET, and PMF are separate diseases or different presentations or different phases of a unique disease. It has been suggested that the phenotype of patients with *JAK2*V617F-positive ET resembles “forme fruste” of PV.\(^54\)

In patients with a clinical picture suggestive of PV and who were found to be negative for the *JAK2*V617F mutation, several genetic abnormalities (ie, mutations, deletions, insertions) have been detected in a short region of *JAK2* exon 12 (Fig. 1B).\(^16\),\(^55\) These mutations, which probably account for less than 2% of patients with PV,\(^55\) affect autonomous cell proliferation and differentiation in a fashion similar to that of the V617F allele.\(^16\)

Another recurrent molecular abnormality of MPN is represented by somatic mutations at codon 515 of *MPL*,\(^17\),\(^18\) which, as is the case with *JAK2*V617F, involve early myeloid and lymphoid progenitors.\(^56\)-\(^58\) *MPL* (named after myeloproliferative leukemia virus oncogene homolog) is the receptor for the cytokine thrombopoietin (Tpo) and is highly expressed in early hematopoietic progenitors and in cells of the megakaryocytic lineage.\(^59\) The two most common *MPL* mutations, which are located in the cytoplasmic juxtamembrane portion, are represented by W515L (a tryptophan to leucine substitution) and W515K (a tryptophan to lysine substitution; Fig. 1B). They have been detected in 5% to 11% of patients with PMF\(^17\),\(^18\),\(^60\) and in up to 9% of *JAK2*V617F-negative cases of ET.\(^61\),\(^62\) Other unusual *MPL* mutations (eg *MPL*W515S, W5151A, and *MPL*S505N, initially discovered in association with inherited familial thrombocytosis) have also been reported.\(^63\) *MPL*W515L induced both cytokine-independent growth and Tpo hypersensitivity in cell lines, resulting in constitutively activated JAK-STAT/ERK/Akt signaling pathways,\(^64\) and caused a PMF-like disease in mice.\(^17\) At variance with the *JAK2*V617F transplantation model, the disease induced by *MPL*W515L was characterized by a rapidly fatal course, marked thrombocytosis, leukocytosis, hepatosplenomegaly, and bone marrow fibrosis, all reminiscent of PMF.\(^17\) Interestingly in some patients, multiple *MPL* mutations or the coexistence with *JAK2*V617F allele were described.\(^60\),\(^62\),\(^65\)

The gene encoding for the receptor of platelet-derived growth factor A (*PDGFRA*) is involved in at least four different genetic abnormalities associated with eosinophilia.\(^66\) The most frequent and best characterized abnormality is due to a karyotypically occult microdeletion at chromosome 4q12, where *PDGFRA* is located, resulting in a chimeric *FIP1L1-PDGFRα* fusion gene (Fig. 1B).\(^10\) The latter encodes for an aberrantly activated tyrosine kinase as the consequence of disruption of the autoinhibitory activity encoded by *PDGFRA* exon 12, where the breakpoint is located; this constitutively active ty-
rosine kinase drives autonomous eosinophil progenitor proliferation, possesses transforming properties in vitro, and induces a myeloproliferative disorder with extensive eosinophil proliferation when expressed in transplanted mice. The fusion gene has been demonstrated at the level of hematopoietic stem cell compartment. Also the Beta type of PDGFR has been reported as being involved in rearrangements associated with imatinib-responsive eosinophilia. The PDGFRB is located at chromosome 5q31-32 and may fuse with different partners. One of the most common is the ETV6/TEL gene on chromosome 12p13, which encodes for a transcription factor with nonredundant roles in normal hematopoiesis. The fusion protein constitutively activates the cellular pathways normally associated with PDGFR signaling and has transforming properties when expressed in cell lines.

A D816V mutation located in the catalytic domain of the tyrosine kinase receptor c-Kit occurs in systemic mastocytosis (Fig. 1B). c-Kit is the receptor for stem cell factor, a key cytokine involved in the generation and differentiation of mast cells from primitive hematopoietic progenitors; it is encoded by kit, located at chromosome 4q12. Additional activating kit mutations other than D816V have also been described in SM, acute leukemia, gastrointestinal stromal cell tumors (GIST), and germ cell tumors. The D816V and other homologous mutations induce growth factor independent growth and cell differentiation in mast cell lines through activation of STAT5/PI3K/AKT signaling pathways and a phenotype resembling human SM in murine models.

**Classification of Myeloproliferative Neoplasms**

The 2008 WHO classification for myeloid neoplasms, which incorporates novel information derived from molecular discoveries in BCR-ABL negative “classic” myeloproliferative states and clonal eosinophilic disorders, includes five major entities (Table 2) as follows: the Acute Myeloid Leukemia (AML) and the Myelodysplastic Syndromes (MDS) with their different subtypes, whose listing is outside the scope of this review; the Myeloproliferative Neoplasms (MPN); the category of overlapping Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN); and the Myeloid Neoplasms associated with eosinophilia and specific molecular abnormalities. AML is defined by the presence of either ≥20% blast cells in the bone marrow and/or peripheral blood or certain characteristic cytogenetic abnormalities. The MDSs are recognized and distinguished from MPN primarily on the basis of the presence of tri-lineage dyshematopoiesis in the absence of monocytosis in both bone marrow and peripheral blood. A “nontrivial” formal modification in the 2008 WHO classification has been the substitution of the attribute “neoplasm” for “disease”. In fact, notwithstanding the analysis of the X chromosome inactivation pattern in informative females and other cytogenetic and/or molecular findings that established both “classic” and “nonclassic” myeloproliferative disorders as being clonal stem cell disorders, and the finding that evolution to AML is part of their natural history, the neoplastic nature of these conditions

**TABLE 2. The 2008 World Health Organization Classification for Myeloid Neoplasms**

| 1. Acute myeloid leukemia (AML) and related precursor neoplasms |
| 2. Myelodysplastic syndromes (MDS) |
| 3. Myeloproliferative neoplasms (MPN) |
| 3.1. Chronic myelogenous leukemia (CML), BCR-ABL1 positive |
| 3.2. Polycythemia vera (PV) |
| 3.3. Essential thrombocytopenia (ET) |
| 3.4. Primary myelofibrosis (PMF) |
| 3.5. Chronic neutrophilic leukemia (CNL) |
| 3.6. Chronic eosinophilic leukemia, not otherwise classified (CEL-NOS) |
| 3.7. Mastocytosis |
| 3.8. Myeloproliferative neoplasm, undifferentiable (MPN-u) |
| 4. Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN) |
| 4.1. Chronic myelomonocytic leukemia (CMML) |
| 4.2. Juvenile myelomonocytic leukemia (JMML) |
| 4.3. Atypical chronic myeloid leukemia, BCR-ABL1 negative |
| 4.4. Myelodysplastic/myeloproliferative neoplasm, unclassifiable |
| 4.5. Refractory anemia with ring sideroblasts associated with marked thrombocytosis |
| 5. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 |
| 5.1. Myeloid and lymphoid neoplasms associated with PDGFRA rearrangement |
| 5.2. Myeloid neoplasms with PDGFRA rearrangement |
| 5.3. Myeloid and lymphoid neoplasms with FGFR1 abnormalities |

From Tefferi A and Vardiman JW.
has been mostly dismissed until recently. This belief has most likely represented one of the reasons for the traditionally poor interest in these neoplasms by cancer surveillance programs, agencies granting research support, or pharmaceutical companies.

The four “classic” MPNs (ie, CML, PV, ET, and PMF) should be distinguished from the other “non-classic” MPNs, which include chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia—not otherwise specified (CEL-NOS), systemic mastocytosis (SM), and unclassifiable forms of MPN.91 CML presents very unique characteristics, and it will not be further discussed herein; recent excellent reviews on molecular and therapeutic issues have been published.92-94

### Chronic Neutrophilic Leukemia

CNL is a rare disorder of elderly people characterized by neutrophilic leukocytosis (greater than $25 \times 10^9/L$) made up of greater than 80% mature granulocytes, splenomegaly, and an absence of the Philadelphia chromosome/BCR-ABL fusion gene. Bone marrow biopsy reveals hyperplasia of granulocytic lineage without involvement of other series, and there is an absence of fibrosis or myelodysplastic features. Given the potential for evolution to acute leukemia or progressive refractory leukocytosis, allogeneic stem cell transplantation may be appropriate for younger patients.95,96

### Chronic Eosinophilic Leukemia and Hypereosinophilic Syndrome

Patients who have a persistent absolute eosinophil count of at least $1.5 \times 10^9/L$, after exclusion of reactive eosinophilias or other hematologic disorders, suffer from one of the different forms of primary eosinophilia.97,98 Many patients with nonclonal forms of eosinophilia fall within the category of “idiopathic” hypereosinophilia; the possibility of a T-cell mediated eosinophilia, generally via increased levels of interleukin-5, can be ruled out with adequate studies of T-cell immunophenotyping and T-cell receptor antigen gene rearrangement.99 Conversely, finding a cytogenetic or molecular abnormality would indicate a clonal, myeloproliferative, eosinophilic disorder.98 Diagnosis of CEL not otherwise (molecularly) specified rests on the demonstration of a cytogenetically abnormal proliferation of eosinophilic precursors with a myeloblast count of 5% to 19% in the bone marrow or greater than 2% in peripheral blood, usually accompanied by evidence of organ damage.97 However, because of intrinsic difficulties in establishing the presence of a clonal disorder when the most frequent molecular abnormalities associated with eosinophilia are lacking (see below), it is likely that many forms of CEL-NOS actually fall improperly within the idiopathic hypereosinophilic syndrome (HES) category.100 Documentation of target organ damage is necessary for a patient to be considered as suffering from HES. Clinical manifestations are related to eosinophilic infiltration of target tissues and may range from almost asymptomatic disease to fatal endomyocardial tissue fibrosis. Bone marrow biopsy reveals eosinophilia without involvement of other cell lines, absence of immature myeloid cells or dysplasia, and a normal number of mast cells. Therapy is based on corticosteroids as first-line therapy, interferon-alpha, or hydroxyurea in refractory or steroid-dependent patients; some patients may respond to imatinib.101 Use of monoclonal antibodies to interleukin-5 (mepolizumab)102 or CD52 (the receptor for interleukin 2; alemtuzumab)103 has produced appreciable results in refractory cases.66

### Mast Cell Disease

Mast cell disease, which is defined by tissue infiltration by abnormal mast cells, can be broadly classified into cutaneous mastocytosis (CM) and systemic mastocytosis (SM); the latter might have an indolent or an aggressive clinical course depending on the absence or presence, respectively, of impaired organ function.104 Life expectancy is nearly normal in indolent forms of SM but is significantly shortened in aggressive SM. The bone marrow is almost universally involved in SM and is characterized by dense, multifocal aggregates of morphologically and immunophenotypically abnormal mast cells, preferentially in a perivascular location, and is often accompanied by increased eosinophils. Serum levels of tryptase are typically high and represent a clinically useful disease-related marker. By using adequately sensitive molecular techniques (such as allele-specific polymerase chain reaction [PCR] amplification of DNA) and mast cell–enriched sources (such as bone marrow aspirate or biopsied lesional material), the kit D816V mutation is detected in virtually all patients with
In addition to its diagnostic value, clinical relevance of searching the D816V kit mutation lies in the almost universally reported refractoriness of mutated patients to imatinib. Conversely, rare patients with other mutations that are located in the c-Kit juxtamembrane portion may respond to treatment with imatinib. Treatment of systemic mastocytosis is highly individualized and largely palliative, aiming to prevent or reduce symptoms due to mast cell degranulation or organ infiltration. Therapeutic options are represented by interferon-alpha or cytotoxic drugs, such as cladribine, but clinical responses are limited.

**Myelodysplastic/Myeloproliferative Neoplasms**

MDS/MPN neoplasms are defined by simultaneous presence of both myelodysplastic and myeloproliferative features that exclude them from being categorized as either MDS or MPN alone. MDS/MPN neoplasms comprise chronic myelomonocytic leukemia (CMML), juvenile MML (of pediatric interest and, thus, not further discussed here), atypical CML, and unclassified MDS/MPN. The clinical and hematologic presentation of MDS/MPN is pleomorphic, with cytopenia and dysplasia of any cell lineage eventually becoming associated with elevated leukocyte or platelet count. Symptoms may be attributed to cytopenias (anemia, infections, hemorrhage) and/or to myeloproliferation (organomegaly, systemic symptoms, cardiovascular events). The molecular basis of these disorders is largely unknown, apart from the involvement of ras pathway with mutations of RASt in CMML and PTPN11 mutations in JMML, or the uncommon presence of JAK2V617F mutation. Therefore, diagnosis relies on a combination of hematological, clinical, and histological criteria.

The typical manifestation of CMML is peripheral blood monocytosis greater than $1 \times 10^9/L$ and a percentage of monocytes in the white blood cell count of greater than 10%. Monocytes may or may not display signs of dysplasia, but the percentage of immature monocytes (promonocytes) and monoblasts in peripheral blood is less than 20%. Both monocytic and granulocytic hyperplasia are found in the bone marrow with a total blast count of less than 20%; signs of erythroid and megakaryocytic dysplasia are variably present. Random cytogenetic abnormalities can be discovered in 20% to 40% of these patients. The prognosis is unfavorable with a median survival of only 2-4 years; a major determinant of survival is the percentage of blood and bone marrow blasts. Hypomethylating agents like decitabine and azacitidine are now approved for treating CMML. Response rate varies from 10% to 30%, depending on the drug and the schedule used, with best results reported for decitabine when a high-dose intensity regimen is used. Treatment is well tolerated with relatively few nonmyelosuppressive complications and has become a valuable therapeutic option for a disease where just a few years ago the standard of care was merely supportive.

Atypical CML is a rare, aggressive disorder with a median survival of 1-2 years and usually affects elderly patients. It presents features typical of classic CML, but unlike classic CML, it is BCR/ABL negative and displays manifest signs of dysgranulopoiesis with nuclear aberrations and cytoplasmic hypogranulation. JAK2V617F mutation is absent. The bone marrow is hypercellular; dysplasia of myeloid lineage with less than 20% blasts is a constant feature, whereas other lineages are variably involved. The disease terminates in AML in up to 40% of these patients.

Refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) is a rare syndrome characterized by anemia with dyserythropoiesis and ring sideroblasts in the bone marrow, associated with thrombocytosis and increased number of large megakaryocytes. These morphologic features of megakaryocytes are distinct from the appearance typically associated with the 5q- abnormality. A high proportion of patients have the JAK2V617F mutation, although a few harbor the MPL mutation. RARS-T is a disease with a relatively good prognosis, and it shares many aspects with classic MPN.

Finally, when myelodysplastic and myeloproliferative features simultaneously present in bone marrow aspirate do not fit into any of the previous categories, and after any known molecular or cytogenetic abnormality is excluded, the disorder is defined as MDS/MPN unclassifiable, with a comment describing the atypical features.
Myeloid Neoplasms Associated with Eosinophilia and Specific Molecular Abnormalities

Both the alpha (PDGFRα) and beta (PDGFRβ) types of platelet-derived growth factor receptor (PDGFR) genes may be involved in genetic abnormalities associated with eosinophilia.121 Eosinophilia associated with FIP1L1-PDGFRα rearrangement has a strikingly male predominance. In addition to an expanded eosinophilic lineage, the bone marrow often contains an increased number of mast cells that, together with findings of raised serum levels of tryptase, sometimes make problematic the differential diagnosis with SM.122 However, at variance with kit D816V-mutated forms of SM, presence of the FIP1L1-PDGFRα mutation reliably predicts hematologic and molecular remission when imatinib is used at doses lower than those used for CML (100 mg daily is generally efficacious).123 The rate of complete molecular response may be as high as 95%, and a prospective multicenter study showed it to be stable and durable during a median follow-up of 25 months but to be dependent on treatment continuation. In three patients who discontinued imatinib, molecular negativity was lost and then regained after imatinib was resumed.124 A definitely lower proportion of patients with imatinib-responsive eosinophilia have rearrangements involving the PDGFRβ gene. Finally, translocations involving the fibroblast growth factor receptor-1 gene (FGFR1), which is located at chromosome 8p11, and several different gene partners are at the basis of the “8p11 myeloproliferative syndrome”.125 This is also called “stem cell leukemia/lymphoma syndrome” because of the clinical phenotype that is characterized by features of both lymphoma and eosinophilic myeloproliferation. The disease results from constitutive activation of the tyrosine kinase domain of FGFR1 after its juxtaposition with any partner gene. Prognosis is very poor with most patients progressing to overt AML or lymphoblastic lymphoma with 1-2 years of diagnosis.126

The “Classic” Myeloproliferative Neoplasms

Among classic MPNs, PV and ET are relatively indolent disorders,127 resulting in a modest reduction of lifespan compared with a control population; however, most patients ultimately suffer from one or more severe and potentially fatal complications directly attributable to the disease. Conversely, PMF has a severe course in most cases, and survival is significantly affected. The three clinical entities share several common features,6 such as their origin in a multipotent hematopoietic stem cell, a relatively normal cellular maturation, a striking overlap in clinical presentation (apart from PMF, which has its own peculiar manifestations), and in cases of PV and ET, the propensity to evolve into post-polycythemic or post-thrombocytopenic myelofibrosis (or less frequently each into the other), and the possibility to transform into AML.90

Epidemiology

Classic MPNs are among the most frequent hematologic neoplasms, usually affecting the adult elderly population; however, they can also be found in children, and in this instance, they raise specific diagnostic and management issues128,129 that are beyond the scope of this review. A recent study,130 based on the North American Association of Central Cancer Registries (NAACCR) encompassing 82% of total US population, reported an average 2001-2003 annual age-adjusted incidence rate of 2.1 per 100,000 and estimated that there were 6,328 new cases in the total US population in 2004. Furthermore, because of their relatively smooth clinical course, it is likely that many classic MPN cases actually go undetected or are not reported to registries. Advanced age, male sex, and white race were identified as risk factors. Among individuals aged 80 years or older, the rate was as high as 13.3 per 100,000. Familial clustering of these disorders is known, and even before the discovery of JAK2V617F mutation,131 this observation led to a suggestion of predisposition allele(s).132 This hypothesis gained substantial support from a large study recently completed in Sweden.133 Relatives of patients with MPN had a 5.7 relative risk (RR) of having PV, an RR 7.4 for ET, and an RR of 7.5 for unclassified forms of MPN, together with a borderline increased RR of CML. The higher risk observed among siblings would suggest a model of recessive inheritance, although whether presentation of disease occurs at an even younger age than in parents is debatable.133,134 Accordingly, thorough investigation of family history is mandatory in the initial workup of patients with classic MPN, and appropriate counsel-
ing should be provided. The coexistence of different clinical entities and of JAK2V617F-positive and JAK2V617F-negative diseases in the same family is noteworthy.131,134,135

Diagnosis

Because of similarities with reactive forms characterized by an increased count of mature peripheral blood cells on one side, and the significant phenotypic overlapping among them on the other, diagnosis of different MPNs has traditionally been challenging; the availability of the new molecular markers is expected to facilitate diagnosis (Table 3). As a matter of fact, molecular genotyping is integral to the 2008 WHO diagnostic criteria,136 and tests for JAK2 or MPL mutation already have become a standard tool in the diagnostic work up of MPN (Fig. 2).137 In fact, detection of one of these mutations unequivocally establishes by itself the presence of a clonal MPN and rules out the possibility of reactive erythrocytosis, thrombocytosis, or myelofibrosis. Unfortunately, they are of no help in distinguishing among the different forms of MPNs, although JAK2 exon12

| TABLE 3. 2008 WHO Diagnostic Criteria for “classic” MPN |
|---------------------------------------------------------|
| **CRITERIA** | **POLYCYTHEMIA VERA** | **ESSENTIAL THROMBOCYTHEMIA** | **PRIMARY MYELOFIBROSIS** |
| Major criteria | 1. Hgb > 18.5 g/dL (men) or >16.5 g/dL (women) or Hgb or Hct > 99th percentile of reference range for age, sex, or altitude of residence or Hgb >17 g/dL (men) or >15 g/dL (women) if associated with a documented and sustained increase of >2 g/dL from baseline that cannot be attributed to correction of iron deficiency or elevated red cell mass >25% above mean normal predicted value | 1. Sustained platelet count ≥450 x 10^9/L | 1. Megakaryocyte proliferation and atypia* accompanied by either reticulin and/or collagen fibrosis or In the absence of reticulin fibrosis, the megakaryocyte changes must be accompanied by increased marrow cellularity, granulocytic proliferation and often decreased erythropoiesis (ie, pre-fibrotic cellu- 
| | | 2. BM showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes. No significant increase or left-shift of neutrophil granulopoiesis or erythropoiesis | 3. Not meeting the WHO criteria for PV, PMF, CML, or MDS or other myeloid neoplasm |
| | | 3. Demonstration of JAK2V617F or other clonal marker | 4. Demonstration of JAK2V617F or other clonal marker or no evidence of reactive thrombocytosis |
| Minor criteria | 1. BM showing hypercellularity for age and trilineage growth (pammyelosis) | | 1. Leukoerythroblastosis |
| | 2. Subnormal serum Epo level | | 2. Increased serum LDH |
| | 3. EEC growth | | 3. Anemia |
| | | | 4. Palpable splenomegal 

WHO indicates World Health Organization; MPN, myeloproliferative neoplasm; CML, BCR-ABL1 chronic myelogenous leukemia; PV, polycythemia vera; PMF, primary myelofibrosis; MDS, myelodysplastic syndrome; BM, bone marrow biopsy specimen; Epo, erythropoietin; EEC, endogenous erythroid colonies; LDH, lactate dehydrogenase.

*Small to large megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous, or irregularly folded nuclei and dense clustering.

FIGURE 2. Rationale for using JAK2V617F genotyping in the diagnostic work-up of suspected MPN. See text for details.
mutations have not yet been reported outside PV, and no patient with PV has been found to harbor an MPL mutation. In patients with evidence of increased red cell mass, according to WHO criteria, demonstration of JAK2V617F mutation allows a diagnosis in greater than 95% of cases, as less than 2% of PV patients harbor JAK2 exon 12 abnormalities. It is debated whether a diagnosis of PV can still be tenable in the absence of JAK2 mutation.

The compelling criterion for a diagnosis of ET is a sustained platelet count of greater than 450 × 10⁹/L. Notably, this value is lower than the one originally used by the 2001 WHO classification system (600 × 10⁹/L), because the latter might have led to inadvertently overlooking classic ET cases with a lower platelet count. This assumption is supported by the discovery of the JAK2V617F mutation in some subjects who have a platelet count lower than 600 × 10⁹/L. Diagnosis of ET requires exclusion of reactive thrombocytosis as well as of other MPNs that present with thrombocytosis. In particular, exclusion of CML with FISH or PCR analysis for BCR-ABL rearrangement is mandatory. Positivity for JAK2V617F or MPL mutation cumulatively account for 60% to 70% of ET cases. Therefore, the assessment of bone marrow morphology remains key to the diagnosis of ET; bone marrow cellularity is normal or slightly increased, with abundance of large, mature-appearing megakaryocytes devoid of morphological abnormalities and generally dispersed throughout the biopsy. This appearance is distinct from both the panmyelosis typical of PV or the predominant granulocytic hyperplasia with highly bizarre megakaryocytes, often found in abnormally tight clusters, with aberrant nuclear to cytoplasmic ratio and hyperchromatic, bulbous, or irregularly folded nuclei that are found in PMF, even in initial stages without overt fibrosis.

Bone marrow histology is required for the diagnosis of PMF. Although advanced reticulin or collagenic fibrosis is typically associated with classic stages of PMF, some degree of reticulin fibrosis can be found as well in PV, or more occasionally in ET. Therefore, fibrosis by itself is not synonym for PMF, and diagnosis of PMF can be made even in the absence of overt fibrosis. Also the leukoerythroblastic features of blood smears, with immature myeloid precursors, nucleated red cells, and abnormally shaped erythrocytes (tear-drop cells), is very characteristic, but not diagnostic, of PMF. CML should be ruled out through BCR-ABL rearrangement analysis, while finding a positive JAK2V617F or MPL mutation allows exclusion of reactive forms of myelofibrosis (such as in infectious or inflammatory processes, metastatic cancer, and lymphoid disorders). Some cytogenetic abnormalities, such as del(13)(q12;q22), are frequently encountered and may be diagnostically specific in this context. Anemia, palpable splenomegaly, and raised lactate dehydrogenase levels are additional diagnostic criteria.

**Clinical Course and Risk Stratification**

Thrombosis, hemorrhage, evolution to post-polycythemic or post-thrombocythemic myelofibrosis, and AML transformation represent the most clinically relevant issues in the course of classic MPN. Most thrombotic events occur at or in the two years before diagnosis. However, epidemiologic inference from the European Collaboration on Low-dose Aspirin in Polycythemia (ECLAP) study and the UK Medical Research Council Primary Thrombocythemia-1 (MRC PT-1) study suggested that the cumulative rate of thrombosis during the disease course ranged from 2.5% to 5.0% and from 1.9% to 3% per patient-year in PV and ET, respectively, depending on whether the patient was in a low-risk or high-risk category. In a large retrospective study of PV or ET patients who had suffered from a previous cardiovascular event, the calculated recurrence rate was 5.6% patient-year with a cumulative probability of 49.9% at 10 years. Arterial thrombosis accounts for 60% to 70% of all cardiovascular events and includes acute myocardial infarction, ischemic stroke, and peripheral arterial occlusion. Events involving the venous system, more common among PV patients, are represented by lower extremity deep venous thrombosis, pulmonary embolism, and splanchnic vein thromboses (SVT, which includes portal vein thrombosis, mesenteric thrombosis, and thrombosis of the hepatic veins causing Budd-Chiari syndrome). The prevalence of SVT is unusually high among MPN patients; however, diagnosis is often complicated by the hemodilution resulting from hypersplenism that makes blood cell counts unreliable, in particular as concerns evidence of increased red cell mass necessary for the diagnosis of PV. Recent data indicate that at least 40% of patients with SVT...
not attributable to other causes actually harbor the JAK2V617F mutation; therefore, JAK2V617F genotyping represents a first-line test for these conditions.\textsuperscript{154,155} Occasional SVT patients harboring MPL mutation have also been reported.\textsuperscript{156} Conversely, involvement of the microcirculatory system is more typically associated with ET and manifests as erythromelalgia (a rare disorder characterized by burning pain, warmth, and redness of the extremities due to arteriolar fibrosis and occlusion with platelet thrombi, typically aspirin-sensitive),\textsuperscript{157} transient ischemic attacks, visual or hearing transitory defects, recurrent headache, and peripheral paresthesia; however, because of the lack of objective diagnostic criteria, true incidence of microvessel disturbances is difficult to assess.\textsuperscript{158} Pathogenesis of thrombosis in classic MPNs is multifactorial; rheologic abnormalities due to increased red cell mass in PV, abnormal function of platelets and their enhanced interaction with leukocytes and endothelial cells, are all possible contributing factors;\textsuperscript{159} however, neither thrombocytosis nor increased hematocrit (at least until 52%) are clearly associated with occurrence of thrombosis.\textsuperscript{160}

Mortality rate is age-dependently increased in PV, being 1.6-fold and 3.3-fold higher than in the reference population in patients younger or older than 50 years, respectively.\textsuperscript{161} Conversely, survival of ET patients is reduced by about 2-fold compared with the general population starting from the first decade after diagnosis.\textsuperscript{162} Major causes of shortened survival in PV or ET are represented by thrombotic events and transformation to myelofibrosis or AML, which account for 41% and 13% of total deaths among 1,638 PV patients that were included in the observational arm of the ECLAP study.\textsuperscript{146,163} An age of greater than 60 years and leukocytosis were incorporated in a predictive model for survival in ET that discriminated groups of patients with median survivals of 25, 17, and 10 years, respectively.\textsuperscript{162} Therefore, because of the finding that thrombosis represents the most common event that complicates the courses of PV and ET, and eventually is the leading cause of death, it seems appropriate to use this clinical endpoint as the criterion for stratifying patients according to their risk.\textsuperscript{164} Older age (greater than 60 years) and a previous history of thrombosis are standard risk factors for thrombosis in both PV and ET (Table 4), which have been validated in several studies.\textsuperscript{146,148,165} In the presence of either of these, a patient is at high-risk, whereas when neither of these is present, the disease is low-risk. The role of generic cardiovascular risk factors, such as hypertension, diabetes, hyperlipidemia, smoking, or genetic alterations of hemostatic factors, is still controversial; however, patients who present with any of these abnormalities are prudentially considered to belong to an intermediate-risk category,\textsuperscript{158,166} and both specific medical intervention and correction of life style issues, particularly smoking, should be aggressively pursued. Recent studies have demonstrated that leukocytosis is an additional independent risk factor for thrombosis,\textsuperscript{162,167,168} particularly for acute myocardial infarction in PV. Furthermore, “low-risk” ET patients could be separated into two categories with a respective overall prevalence of thrombosis of 55% and 20% depending on the presence, or not, of an absolute leukocyte count greater than 8.7 \times 10^9/L.\textsuperscript{169} Finally, there is also evidence that JAK2V617F mutated status in ET,\textsuperscript{47,170,171} and a high V617F allelic burden in both ET\textsuperscript{47,172} and PV\textsuperscript{172-173} are associated with increased risk of thrombosis. Therefore, both leukocytosis and JAK2V617F mutated status represent novel, powerful, disease-associated, risk factors; however, before they are included in current risk stratification criteria outlined in Table 4, they need validation in prospective studies.

Life expectancy in PMF is 31% lower than in an age-matched and sex-matched population, with a median survival of 5 years, although younger patients may experience longer survival.\textsuperscript{161,174,175} Major causes of death are represented by the sequelae of portal hypertension or hepatic-splenorenal thrombosis, thromboses in various anatomic sites, heart failure due to splenic pooling, infections, pulmonary hypertension, bleeding caused by thrombocytopenia or hemostatic defects, and transformation to AML.\textsuperscript{147} Prognostic staging systems for PMF have been developed that allow separation of patients with low-

\begin{table}[ht]
\centering
\caption{Risk-Stratification of Patients with Polycythemia Vera or Essential Thrombocytopenia}
\begin{tabular}{|c|c|c|}
\hline
\textbf{RISK CATEGORY} & \textbf{AGE > 60 YEARS OR HISTORY OF THROMBOSIS} & \textbf{GENERIC CARDIOVASCULAR RISK FACTORS} \\
\hline
Low & No & No \\
Intermediate & No & Yes \\
High & Yes & Irrelevant \\
\hline
\end{tabular}
\end{table}
risk and high-risk disease associated with significantly different survival times (Table 5). The most used “Lille score” includes anemia and abnormal leukocyte count as variables and effectively distinguishes patients with survival times that range from 1–8 years.176 Stratification according to risk is of particular importance in younger patients who may potentially exploit the curative efficacy of allogeneic hematopoietic stem cell transplantation (HSCT). In this regard, “Cervantes”175 and “Mayo” ad hoc scoring systems for patients aged younger than 55 years or 60 years have been developed177 and represent useful instruments to aid both physician and patient to make the most appropriate therapeutic decision (Table 5). Presence of a JAK2V617F mutated state independently predicted leukemic transformation in a longitudinal prospective series of PMF patients,178 whereas presence of MPLW515L/K mutation was associated with more severe anemia.60 However, because of conflicting results reported in similar studies,179 these markers need further validation before being operationally incorporated into prognostic systems.

Transformation to post-polycythemic or post-thrombocytemic myelofibrosis represents the natural evolution of PV and ET, occurring late in the clinical course. The estimated rate is about 5% after 15 years from diagnosis of PV,146 whereas data are scanty in ET. Criteria for the diagnosis of evolution to myelofibrosis have recently been proposed by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT; Table 6).180 Survival is probably shortened by the development of myelofibrosis, and may be predicted by hemoglobin level and platelet and leukocyte counts according to a dynamic prognostic model recently developed in PV patients.183 Evolution to AML occurred in 1.3% of PV patients included in ECLAP study, at a median time of 8.4 years after diagnosis;163 however, because of the short follow up, a precise estimate cannot be made, and information about ET is not yet available. Survival time is dismal, less than 6 months, although recipients of allogeneic HSCT may experience longer remission.184 Advanced age, elevated leukocyte count, and longer disease duration were factors associated with increased risk of leukemic transformation.163 An increased risk of AML was reported in patients who were treated with radioactive phosphorus or chlorambucil in the PVSG trial.185 In addition, sequential or combined use of more

**TABLE 5. Prognostic Scoring Systems Used for Risk Assessment in Patients with PMF**

| PROGNOSTIC SCORING SYSTEM | PROGNOSTIC FACTORS | NO. OF PROGNOSTIC FACTORS BY RISK CATEGORY | NO. OF MONTHS OF SURVIVAL BY RISK CATEGORY |
|---------------------------|--------------------|------------------------------------------|------------------------------------------|
| All patients              |                    | LOW | INTERMEDIATE | HIGH | LOW | INTERMEDIATE | HIGH |
| Lille                     | Hb <10 g/dL, WBC <4 or >30x10^9/L | 0   | 1 | 2 | 93 | 26 | 13 |
| Cervantes                 | Hb <10 g/dL, PB Blasts >1% Constitutional symptoms | 0-1 | — | 2-3 | 99 | — | 21 |
| Mayo                      | Hb <10 g/dL, WBC <4 or >30x10^9/L, Plt <100x10^9/L, Monocytes >1x10^9/L | 0 | 1 | 2 | 173 | 61 | 26 |
| Younger patients          |                    |                |                |                |                |                |                |
| Cervantes, aged ≤55 y     | Hb <10 g/dL, PB Blasts >1% Constitutional symptoms | 0-1 | — | 2-3 | 176 | — | 33 |
| Dingli, aged <60 y        | Hb <10 g/dL, WBC <4 or >30x10^9/L, Plt <100x10^9/L | 0 | 1 | 2-3 | 155 | 69 | 24 |

Constitutional symptoms included unexplained fever, night sweats, or weight loss of greater than 10% of baseline value in the last 6 months.

PMF indicates primary myelofibrosis; Hb, hemoglobin; WBC, white blood cell count; PB Blasts, percentage of blasts in peripheral blood smears; Plt, platelet count.
than one chemotherapeutic agent, including hydroxyurea (HU), significantly increased the rate of evolution to AML in PV patients in the observational arm of ECLAP study.\textsuperscript{186}

Management of Classic MPN

Over the years, there has been a shortage of clinical studies specifically devoted to classic MPN. Most available information derives from a limited number of randomized clinical trials performed within national or international collaborative groups that include the Polycythemia Vera Study Group (PVSG),\textsuperscript{165,186} the ECLAP study,\textsuperscript{146,149} the “Bergamo trial,”\textsuperscript{187} and the PT-1 trial\textsuperscript{150}; however, the information they have provided represents the foundation for current treatment indications\textsuperscript{189-192} as well as the basis for future studies (Table 7). Standardized criteria for assessing clinical and hematologic responses in PMF have been published\textsuperscript{193,194} and will be of particular relevance for evaluation of novel molecularly target drugs. Conversely, similar criteria for patients with PV or ET are still lacking.

Cytoreductive Therapy in PV and ET

Treatment of patients with PV or ET should adhere to the standard risk stratification outlined above (Table 4). Phlebotomy is the cornerstone of treatment in low-risk patients with PV, aimed at reaching and maintaining a target hematocrit of less than 45% in men and less than 42% in women, according to standard recommendations.\textsuperscript{165} The ultimate goal of this practice is to limit availability of iron to erythropoiesis, but often it will cause symptoms due to severe and prolonged iron deficiency; fatigue is being recognized as one major burden for quality of life in patients with PV.\textsuperscript{127} In fact, there is wide variability in opinions and attitudes among US and non-US physicians concerning the optimal hematocrit target to be attained with phlebotomies.\textsuperscript{195} Conversely, high-risk patients should receive myelosuppressive therapy, eventually in association with phlebotomy, and hydroxyurea (HU) is the drug of choice (Table 7). HU is an antimetabolite that prevents synthesis of DNA. It is also approved for the treatment of sickle cell anemia because of its capacity to reactivate synthesis of hemoglobin F, resulting in a significant decrease of occlusive and hemolytic events.\textsuperscript{196} Superiority of HU compared with phlebotomy was suggested in a comparative analysis of the PVSG in the 1980s,\textsuperscript{185} but no randomized trial to address this issue has yet been undertaken.

### TABLE 6. Criteria for Establishing the Diagnosis of Evolution to Post-polycythemic or Post-thrombocythemic Myelofibrosis According to IWG-MRT Criteria\textsuperscript{180}

| CRITERIA FOR POST-POLYCYTHEMIC MYELOFIBROSIS |
|-----------------------------------------------|
| Required criteria |
| 1. Documentation of a previous diagnosis of polycythemia vera as defined by WHO criteria\textsuperscript{136} |
| 2. Bone marrow fibrosis grade 2-3 (according to the European classification\textsuperscript{181}) or grade 3-4 (according to standard classification\textsuperscript{182}) |
| Additional criteria |
| 1. Anemia (below the reference range for appropriate age, sex, and altitude considerations) or sustained loss of either phlebotomy (in the absence of cytoreductive therapy) or cytoreductive treatment requirement for erythrocytosis |
| 2. A leucoerythroblastic peripheral blood picture |
| 3. Increasing splenomegaly of \( \geq 5\) cm (distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly |
| 4. Development of \( \geq 1\) of 3 constitutional symptoms: \( \geq 10\% \) weight loss in 6 months, night sweats, unexplained fever (\( \geq 37.5°C\)) |

| CRITERIA FOR POST-THROMBOCYTHEMIC MYELOFIBROSIS |
|-----------------------------------------------|
| Required criteria |
| 1. Documentation of a previous diagnosis of essential thrombocythemia as defined by WHO criteria\textsuperscript{136} |
| 2. Bone marrow fibrosis grade 2-3 (according to the European classification\textsuperscript{181}) or grade 3-4 (according to standard classification\textsuperscript{182}) |
| Additional criteria |
| 1. Anemia (below the reference range for appropriate age, sex, and altitude consideration) and a \( \geq 20\) g/L decrease from baseline hemoglobin level |
| 2. A leucoerythroblastic peripheral blood picture. |
| 3. Increasing splenomegaly of \( \geq 5\) cm (distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly |
| 4. Increased LDH (above reference level) |
| 5. Development of \( \geq 1\) of 3 constitutional symptoms: \( \geq 10\% \) weight loss in 6 months, night sweats, unexplained fever (\( \geq 37.5°C\)) |

Diagnosis is made on the basis of meeting all required criteria plus two additional criteria.

WHO indicates World Health Organization; LDH, lactate dehydrogenase.
The use of low-dose aspirin in PV was exploited in the ECLAP study that randomized 518 low-risk patients in a double-blind, placebo-controlled trial. The primary study endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and major venous thromboembolism) was significantly lowered by aspirin (RR, 0.40; 95% confidence interval [CI] 0.18 to 0.91; \(P = 0.02\)), with only a small, nonsignificant increase of major hemorrhage (RR, 1.62; 95% CI, 0.27 to 9.71; \(P = 0.60\)); total and cardiovascular mortality were also reduced by 46% and 59%, respectively. Therefore, in the absence of a history of major bleeding, allergy to the drug or severe asthma, or gastric intolerance, low-dose aspirin (100 mg daily) is recommended regardless of risk category for all patients with PV.

Low-risk patients with asymptomatic ET do not need therapy, although high-risk patients have the same indications for the use of HU as patients with PV. In the “Bergamo trial,” which randomized 114 high-risk patients to HU versus no treatment, the percentage of patients who developed thrombosis decreased from 24% to 3.6%. HU was also superior to anagrelide, a nonmyelosuppressive platelet-lowering drug, in preventing arterial thrombosis in the randomized MRC-PT-1 trial, which included 809 high-risk patients, although venous thrombosis was reduced in the anagrelide arm. Interestingly, JAK2V617F-positive patients had a better response and required lower doses of HU to control thrombocytosis compared with patients who did not have this mutation. The target level at which the platelet count should be maintained with therapy in high-risk patients is currently set at 400–450 × 10^9/L, but this is not based on evidence. Also, there is little rationale for the use of cytoreductive treatment to reduce extreme thrombocytosis (platelet count greater than 1,000 × 10^9/L) in an otherwise low-risk, asymptomatic patient.

Unlike PV, the safety and efficacy of low-dose aspirin use for ET has not formally been proven, but most patients in intermediate-risk or high-risk categories are currently advised to use the drug. Higher doses, up to 500 mg daily, may be required for acute symptoms because of microvascular disturbances, in particular erythromelalgia. Conversely, extreme thrombocytosis is considered a contraindication for aspirin use because of a possibly increased bleeding tendency due to acquired Von Willebrand disease.

There has been some debate about potential leukemogenicity of HU, but although current evidence does not attribute to the drug a definite risk in this regard, it is appropriate to reserve HU use for patients at high risk of developing complications and in whom benefits expected from treatment overcome potential unwanted effects. Actually, transformation to AML is considered part of the natural history of MPN.

Noncytotoxic Drugs for PV and ET

Interferon-alpha (IFN-\(\alpha\)), a nonleukemogenic agent, has multiple potential activities against hematopoietic progenitor cell proliferation and differentiation which may justify its use in the youngest of patients with PV and ET. However, tolerance is often poor because of acute and chronic side effects that cause discontinuation of the drug in one-third of patients. IFN-\(\alpha\) has been shown to effectively reduce the hematocrit or platelet count to a target level in the majority of cases, and no thrombohemorrhagic events were recorded among 55 patients with PV who were followed for a median of 13 years. Progressive decrease of JAK2V617F burden has been suggested in one study, whereas changes were minimal in another study. Notably, a recent, phase 2, multicenter study that used pegylated-IFN-\(\alpha\) in 40 patients with PV reported complete molecular remission in 7 of these patients. Finally, because IFN-\(\alpha\) is not teratogenic and does not cross the placenta, it is recommended whenever there is the need for cytoreduction during pregnancy, according to current guidelines.

Anagrelide has widely been used to control platelet count in patients with ET in all risk categories; the

### TABLE 7. Risk-Oriented Therapy in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

| RISK CATEGORY | RISK FACTORS | PV | ET |
|---------------|--------------|----|----|
| Low           | Age <60 y and no prior cardiovascular event | Phlebotomies plus low-dose aspirin | Nil, or low-dose aspirin (no consensus) |
| Intermediate  | Generic cardiovascular risk factors | Low-dose aspirin (no consensus) | Low-dose aspirin (no consensus) |
| High          | Age >60 y and/or prior cardiovascular event | Myelosuppression \(\pm\) Phlebotomies | Myelosuppression |
|               |              | Low-dose aspirin | Low-dose aspirin |
majority of patients achieved adequate control of thrombocytosis, although cardiovascular side effects (mainly palpitations and headache, less frequently congestive heart failure) may require early discontinuation of treatment.\textsuperscript{211,212} The drug is considered devoid of any leukemogenic potential, but it should not be prescribed during pregnancy. On the basis of results of the PT-1 trial, anagrelide is not recommended in high-risk patients as an alternative to HU, and its rationale in otherwise low-risk or intermediate-risk patients should be carefully evaluated case by case.\textsuperscript{213} However, according to recently published guidelines,\textsuperscript{214} anagrelide could be successfully used in platelet count control in patients with PV or ET who are refractory and/or resistant, or who show poor tolerance, or who develop side effects to HU.

Management of PMF

The only approach that has resulted in a prolongation of survival time in PMF and has the potential to be curative is allogeneic HSCT.\textsuperscript{215} At present, it should be reserved for patients with high-risk disease after careful clinical evaluation and thorough patient counseling, particularly considering the option of inclusion in trials with innovative drugs. Both myeloablative and reduced-intensity conditioning regimens have been used, with similar efficacy in terms of survival (3-year event-free survival in the range of 50% to 60%) but lower mortality rate with the use of the latter in older patients.\textsuperscript{216} Therefore, a myeloablative strategy may be considered as the most appropriate for younger patients, whereas the reduced-intensity regimen would be the best for older patients. Furthermore, in patients who relapse after HSCT, a graft-versus-myelofibrosis effect could be demonstrated after donor-lymphocyte infusion with a remarkable reduction of bone marrow fibrosis.\textsuperscript{217,218}

Factors that have been reported as having a favorable impact on overall survival after HSCT include a conditioning regimen with busulfan/cyclophosphamide, younger age, high platelet count, low comorbidity index, low risk according to the Dupriez score, normal karyotype, hemoglobin of greater than 100 g/L, absence of circulating blasts, and absence of osteosclerosis.\textsuperscript{219-221} The usefulness of pretransplant splenectomy still remains controversial.\textsuperscript{215,222,223}

Given that a conventional drug therapy does not significantly modify disease course and is largely ineffective, it is reserved for patients who present either with symptomatic anemia or splenomegaly. Androgens,\textsuperscript{224} prednisone,\textsuperscript{224} erythropoiesis-stimulating agents,\textsuperscript{225-227} and danazol\textsuperscript{228,229} are all variably used with measurable effect in a few patients. Low-dose thalidomide in combination with prednisone improves anemia or thrombocytopenia in 30% to 50% of cases.\textsuperscript{230-234} Lenalidomide, a thalidomide analog, has produced excellent and durable responses in the relatively infrequent PMF patients who have the del(5q) abnormality,\textsuperscript{235} and it can be recommended as first-line therapy in this patient subset. When there is the need to control excessive myeloproliferation, ie, leukocytosis, thrombocytosis, or progressive splenomegaly, HU is the current drug of choice.\textsuperscript{236} Several other drugs, including busulfan,\textsuperscript{237} melphalan,\textsuperscript{238} and 2-chlorodeoxyadenosine,\textsuperscript{239} have been used particularly in HU-refractory patients, but results are generally dismal. Splenectomy has a role for alleviating mechanical symptoms due to extreme splenomegaly and can also ameliorate anemia in approximately 25% of transfusion-dependent patients.\textsuperscript{240} However, splenectomy in PMF bears an approximately 10% procedure-related mortality, and it should be performed by experienced surgeons. Furthermore, up to 25% of patients present with accelerated hepatomegaly and extreme thrombocytosis after splenectomy, and these patients require further cytoreduction.\textsuperscript{240,241} Splenic irradiation is reserved for patients who cannot undergo splenectomy for any reason, but the efficacy of this therapy is poor, and subsequent cytopenias are often severe. Conversely, radiation therapy has a defined role in the treatment of nonhepatosplenic extramedullary hematopoiesis, such as in cases of spinal cord compression by foci of eretropic hematoipoiesis.\textsuperscript{242-245}

Prospect for Molecularly Targeted Therapy in Classic MPN

The involvement of JAK-STAT pathways in most patients who have classic MPN and harbor mutations in JAK2 or MPL and the experimental evidence that suggests that the same signaling abnormalities may be at the basis of mutation-negative patients\textsuperscript{20} are behind active efforts to develop anti-JAK2 drugs. Many molecules have undergone preclinical testing, in vitro and also in vivo, and some have already been introduced into clinical trials.\textsuperscript{246-252} A very incomplete list of molecules that may or may not have selective anti-JAK2 activity is reported in Table 8. Concerning selective JAK2 inhibitors, we have listed only those that are already in clinical trials or whose activity has been demonstrated in...
TABLE 8. Innovative Therapies for Classic MPN

| DRUG             | MAIN TARGETS | IN CLINICAL TRIAL |
|------------------|--------------|-------------------|
| JAK2 selective inhibitors |              |                   |
| INCBO18424       | JAK2         | Yes               |
| XL019            | JAK2         | Yes               |
| TG101348         | JAK2         | Yes               |
| Non-JAK2 selective inhibitors |          |                   |
| CEP-701 (Leustatinib) | FLT3       | Yes               |
| MK-0457          | Aurora Kinase, FLT3, BCR-ABL | Yes |
| Erlotinib        | EGFR         | Yes               |
| ITF2357          | Histone deacetylases | Yes |
| Tipifarnib       | FT           | Yes               |

MPN indicates myeloproliferative neoplasm; FLT3, FMS-like tyrosine kinase 3; EGFR, epidermal growth factor receptor; FT, farnesyl transferase.

JAK2V617F–mutated murine models (TG101348).248

Among these, INCBO18424, XL019, CEP–701, and TG101348 are currently undergoing clinical trials in patients with advanced stages of PMF, post-PV/ET myelofibrosis, PV, and JAK2V617F-positive ET.253-256 Preliminary results have been encouraging in terms of activity against splenomegaly and constitutional symptoms,253 with minimal toxicity. Although the number of patients treated until now is less than 100 with any single drug and, thus, prevents us from making any definitive comment, the hope that this molecularly targeted approach may finally result in improving quality of life and possibly the chance of cure for patients with classic MPN is enormous.

Patient Resources

During the last few years, we have witnessed a renewed interest in the MPN field among scientific communities and pharmaceutical companies; at the same time, the patient community is growing in awareness and strength. There are several focused resources for patient information and support that include the Myeloproliferative Disorders Research Consortium (MPD-RC, an international research consortium funded by the National Cancer Institute; http://www.mpd-rc.org), the Myeloproliferative Disorders Foundation (committed to promoting focused research and international expert cooperation and also devoted to patient education and support; http://www.mpdinfo.org), the Mastocytosis Society (http://www.mpsforacure.org), and several online support groups (such as http://www.acor.org; http://www.mpdsupport.org). Among non-US resources are the Myeloproliferative Disorders Australia (MPD-Oz; http://www.mpd-oz.org), the Italian Mielofibrosi Insieme (for patients with PMF; http://www.mielofibrosi.net), and the Gruppo Italiano per le Malattie Ematologiche Maligne dell’Adulto-GIMEMA (http://www.gimema.org).

REFERENCES

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6:372–375.
2. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia and constitutional symptoms (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31:737–740.
3. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85–109.
4. Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2008;22:3–13.
5. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
6. Spivak JL. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry. Semin Hematol 2003;40:1–5.
7. Kaushansky K. The chronic myeloproliferative disorders and mutation of JAK2: Dameshek’s 54 year old speculation comes of age. Best Pract Res Clin Haematol 2007;20:3–12.
8. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097.
9. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–293.
10. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRα and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201–1214.
11. Nagata H, Worboc AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560–10564.
12. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–397.
13. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005;434:1144–1148.
14. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
15. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
16. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and essential thrombocythemia. N Engl J Med 2007;356:459–468.

17. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.

18. Pardanani AD, Levine RL, Lasjo T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472–3476.

19. Cazzola M, Skoda R. Gain of function, loss of control—a molecular basis for chronic myeloproliferative disorders. Haematologica 2005;90:871–874.

20. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673–683.

21. Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci 2006;63:2399–2393.

22. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007;6:550–566.

23. Salahin P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activator protein 1 target gene transcription. J Biol Chem 2002;277:47954–47963.

24. Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers MG, Jr. Tyrosine phosphorylation of JAK family tyrosine kinases and for cytokine-inducible STAT5 binding activity. Mol Immunol 2000;275:29338–29347.

25. Shuai K, Liu B. Regulation of JAK-STAT signaling. Bioessays 1999;21:47–52.

26. Starr R, Hilton DJ. Negative regulation of the JAK/STAT pathway. Bioessays 1999;21:47–52.

27. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Br J Haematol 2005;137:244–247.

28. Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F-positive myeloproliferative disease. Cancer Res 2006;66:11156–11165.

29. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 2006;1:e18.

30. Tielt T, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2–V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008;111:3931–3940.

31. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2007;67:5625–5632.

32. Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera characterized by JAK2 V617F mutation. N Engl J Med 1974;291:384–389.

33. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4724–4732.

34. Lapout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108:1652–1660.

35. Tiedt R, Hao-Shen H, Sobas MA, et al. Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of JAK2V617F-positive myeloproliferative disease. Br J Haematol 2006;135:683–687.

36. Chaligne R, Tonetti C, Besancenot R, et al. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera. Leukemia 2007;21:1960–1963.

37. Antonioli E, Guglielmelli P, Pancrazzi A, Bergamaschi M, et al. New mutations of MPL in primitive myeloid disorders: only the MPL W515 mutations contribute to phenotypic diversity in essential thrombocythemia. J Clin Invest 2005;115:3339–3347.

38. Tefferi A, Finke C, Markovic SN, et al. Demonstration of subtypes of essential thrombocytemia and relation to polycythemia vera based on JAK2–V617F mutational status: a prospective study. Lancet 2005;366:1945–1953.

39. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2–V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008;111:3931–3940.

40. Vannucci AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F-positive myeloproliferative disease. Cancer Res 2006;66:11156–11165.

41. Pikman Y, Lee BH, Mercher T, Dikic I, Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin receptor and JAK2. J Biol Chem 2002;277:29338–29347.

42. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and essential thrombocythemia. N Engl J Med 1974;291:384–389.

43. New mutations of MPL in primitive myeloid disorders: analysis of the PT-1 cohort. Blood 2008;112:141–149.

44. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring MPL mutations. Br J Haematol 2007;137:244–247.

45. Beer PA, Campbell P, Scott LM, et al. MPL515 mutations in myeloproliferative disorders: extending JAK2V617F and MPL515 mutation analysis to single myeloid colonies and T and B lymphocytes. Stem Cells 2007;25:2358–2362.

46. Chaligne R, James C, Tonetti C, et al. Evidence for MPL W515L/M mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 2007;110:3735–3743.

47. Antonioli E, Lasjo T, Finke CM, et al. Extending JAK2V617F and MPL515 mutation analysis to single myeloid colonies and T and B lymphocytes. Stem Cells 2007;25:2358–2362.

48. Kaushansky K. The molecular mecha- nisms that control thrombopoiesis. J Clin Invest 2005;115:3339–3347.

49. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring MPL mutations. Br J Haematol 2007;137:244–247.

50. Beer PA, Campbell P, Scott LM, et al. MPL515 mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112:141–149.

51. Theocharides A, Boissinot M, Girodon F, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007;35:32–38.

52. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2–V617F-positive myeloproliferative disorders are frequently negative for the JAK2–V617F mutation. Blood 2007;110:375–379.

53. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemia transformation. Blood 2006;108:3548–3555.

54. Pardanani A, Lasjo TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960–1963.

55. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombo- cythemia and relation to polycythemia vera based on JAK2–V617F mutational status: a prospective study. Lancet 2005;366:1945–1953.

56. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and essential thrombocythemia. N Engl J Med 1974;291:384–389.
66. Fletcher S, Bain B. Diagnosis and treatment of myeloproliferative syndromes. Cancer 2007;114:37–42.
67. Buitenhuis M, Verhagen LP, Cools J, Coffier PJ. Molecular mechanisms underlying FIP1L1-PDGFRα-mediated myeloproliferation. Cancer Res 2007;67:3759–3766.
68. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 2003;3:459–469.
69. Robyn J, Lemery S, McCoy JP, et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRα-positive hyper eosinophilic syndrome. Br J Haematol 2006;132:286–292.
70. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with (5;12) chromosomal translocation. Cell 1994;77:307–316.
71. Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the (11;5)(q23;p35) in a myeloproliferative syndrome associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003;102:4187–4190.
72. Wang LC, Swat W, Fujiwara Y, et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev 1998;12:2392–2402.
73. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGFRB delta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFRB delta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A 1996;93:14845–14850.
74. Valent P. Systemic mastocytosis. Cancer 2008;112:399–419.
75. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463–3468.
76. Sihto H, Sarlomo-Rikala M, Tyninnen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005:23:49–57.
77. Harir N, Boudot C, Friedbichler K, et al. Oncogenic Kit controls neoplastic mast cell growth through STAT5/PJ-kinase signaling cascade. Blood 2008;112:2463–2473.
78. Vardiman JW, Harris NL, Bruning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302.
79. Gilliland DG, Blanchard KL, Levy J, Perrin S, Bunin GR. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci U S A 1991;88:6848–6852.
80. Falikow PJ, Cartier SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci U S A 1967;58:1468–1471.
81. Barr RD, Falikow PJ. Clonal origin of chronic myelocytic leukemia. N Engl J Med 1973;288:307–309.
82. Fialkow PJ, Falikow PJ, Murphy S, Prehal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976;295:913–916.
83. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monococyte/macrophage. Am J Med 1977;63:125–130.
84. Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN. Chronic myelocytic leukemia. Origin of clonal leukocytes from leukemic stem cells. J Clin Invest 1978;62:815–823.
85. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978;51:189–194.
86. Martin PJ, Najfeld V, Hansen JA, Penfold GK, Jacobson RJ, Fialkow PJ. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature 1980;287:49–50.
87. Fialkow PJ, Faget GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981;58:916–919.
88. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood 2003;101:1981–1983.
89. Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1549T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007;109:71–77.
90. Tefferi A, Gangat N, Wolanskyj AP, et al. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol 2008;80:386–390.
91. Tefferi A, Elliott MA, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc 2006;81:553–563.
92. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007;370:342–350.
93. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukaemia. N Engl J Med 2007;357:258–265.
94. Kantarjian H, Schiffer C, Jones D, Cortes J. Chronic myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:1794–1803.
95. Tartaglia M, Niemyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia: a critical review of the literature. Leukemia 2005;19:1317–1319.
96. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic hypereosinophilic syndrome. Lancet 2003;362:535–536.
97. Tefferi A, Verstovsek S, Pardanani A. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica 2008;93:6–9.
98. Orazi A, Gerning U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008;22:1308–1319.
99. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al. Ras mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 1990;76:1214–1219.
100. Levin RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:3377–3379.
101. Silverman DR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429–2440.
102. Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a 5-azacytidine analog, in chronic myelomonocytic leukemia. Cancer 2007;109:713–717.
103. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794–1803.
104. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher.
116. Fend F, Horn T, Koch I, Vela T, Orazi A. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Leuk Res 2007;31:189–196.

117. Shaw GR. Ringed sideroblasts with thrombocyto- sisis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005;131:180–184.

118. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of polycythaemia with ringed sideroblasts associated with marked thrombocyto- sisis. Haematologica 2008;93:34–40.

119. Steensma DP, Cauldill JS, Pardanani A, McClure RF, Lasbo TL, Tefferi A. MPL WS15 and JAK2 V617F mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated plate- let count. Haematologica 2006;91:ECR57.

120. Atalaih E, Nussenzevig R, Yin CC, et al. Prognostic impact of platelet count on thrombocyto- sisis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sidero- blasts and marked thrombocyto- sisis. Leuke- mia 2008;22:1295–1298.

121. Goltlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 up- date. Acta Haematol 2005;114:7–25.

122. Tefferi A, Laslo TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A, FIP1L1-PDGFRAlpha, classification by WHO criteria, and re- sponse to therapy with imatinib. Leuk Res 2006;30:1201–1205.

123. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with Philadelphia chromosome-negative hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007;92:1173–1179.

124. Macdonald D, Aguilar RC, Mason PJ, Goldman JM, Cross NC. A new myeloprolif- erative disorder associated with chromoso- mal translocations involving 8p11: a review. Leukemia 1995;9:1628–1630.

125. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a dis- tinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002;107:101–107.

126. Mesa RA, Niblack J, Wadleigh M, et al. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a dis- tinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002;107:101–107.

127. Mesa RA, Niblack J, Wadleigh M, et al. Myelofibrosis with myeloid metaplasia: a rising incidence in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112:45–52.

128. Bellanne-Chantelot C, Chaumarel I, La- bopin M, et al. Genetic and clinical implica- tions of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disor- ders. Blood 2006;108:346–352.

129. Kralovic R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythaemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003;102:3793–3796.

130. Landgren O, Golden LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocyto- sisis, and myelofibrosis among 24577 first-degree relatives of 11039 patients with myeloproliferative neoplasms in Sweden. Blood 2008;112:2199–2204.

131. Rumi E, Passamonti F, Della Porta MG, et al. Familial myeloproliferative disor- ders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007;25: 5630–5635.

132. Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006;107:2206–2211.

133. Swerdlow SH, Campo E, Harris NL, et al. (eds.). WHO classification of tumors of haematopoietic and lymphoid tissues. 4th Edition. IARC, Lyon. 2008.

134. Tefferi A, Vardiman JW. The diagnostic interface between histology and molecu- lar tests in myeloproliferative disorders. Curr Opin Hematol 2007;14:115–122.

135. Wang YL, Vandrish K, Jones A, et al. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 2008;22:1289.

136. Spivak J, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocyto- sisis and primary myelofibrosis: an alterna- tive proposal. Blood 2008;112:231–239.

137. Lengfelder E, Hochhaus A, Kronawitter U, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in patients with splanchic vein thrombosis. Br J Haematol 2005;129:533–540.

138. Kiladjian JJ, Cervantes F, Lebree FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchic vein thrombosis: a report on 241 cases. Blood 2008;11:4922–4929.

139. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchic vein thrombosis. Haematologica 2006;4:1528–1534.

140. Bergamaschi GM, Primignani M, Barosi G, et al. MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood 2008;111:4418–4424.

141. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Ravee H, Schroyens W. Clinical and laboratory fea- tures, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocyto- sisis and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006;32:174–207.

142. Elliot MA, Tefferi A. Thrombocytosis and haemorrhage in polycythaemia vera and essential thrombocyto- sisis. Br J Haema- tol 2005;128:275–290.

143. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114–124.

144. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with aspirin in high-risk essential thrombocyto- sisis. N Engl J Med 2005;353:33–45.

145. Di Nisio M, Barbui T, Di Gennaro L, et al. Thrombocytosis. N Engl J Med 2004;350:1211–1219.

146. Vannucchi AM, Barbui T, Di Gennaro L, et al. Thrombocytosis and polycythemia vera: the natural history of 1213 patients followed for 20 years. Grupo Italiano Studio Policlinico. Ann Intern Med 1995;123:656–664.

147. Cervantes F, Pasamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloprolifera- tive disorders. Leukemia 2008;22:905–914.

148. Wolanksyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocyto- sisis beyond life expectancy: a long-term prospective study. Mayo Clin Proc 2006;81:159–166.
163. Finazzi G, Caruso V, Marchiolli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664–2670.

164. Finazzi G, Barbi T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 2005;19:243–252.

165. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132–143.

166. Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 2005:409–415.

167. Carobbio A, Finazzi G, Barbui T, et al. Leukocytosis is a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446–2452.

168. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 1984;101:932–938.

169. Barbi T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215–232.

170. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative neoplasms: final result of a phase 2 study. Cancer 2007;110:2012–2018.

171. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17–23.

172. Barbi T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004;41:15–17.

173. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17–23.

174. Petitt RM, Gilbert HS, From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17–23.

175. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22:756–761.

176. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22:756–761.
212. Steurer M, Gastl G, Jeddrezczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101:2239–2246.

213. Barbuti T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 2007;33:321–329.

214. Barosi G, Bessis C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007;21:277–280.

215. Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008;22:474–486.

216. Rondelli D, Barosi G, Racigalapulo A, et al. Allogeneic hematopoietic stem-cell transplant with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Bone Marrow Transplant 2005;35:411–419.

217. Byrne JL, Beshit H, Clark D, et al. Induction of remission after donor leukocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs. myelofibrosis’ effect. Br J Haematol 2001;113:430–433.

218. Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000;26:697–699.

219. Deeg HJ, Guardiola P. Allogeneic hematopoietic stem-cell transplantation in patients with myeloplastic syndrome or myelofibrosis. Int J Hematol 2002;76(suppl 2):29–34.

220. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999;93:2831–2838.

221. Barosi G, Racigalapulo A. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Curr Opin Hematol 2006;13:74–78.

222. Ciurea SO, Sadeghi B, Wilbur A, et al. Effects of extensive spleenomegaly in patients with myelofibrosis undergoing a reduced-intensity allogeneic stem cell transplantation. Br J Haematol 2008;141:80–83.

223. Li Z, Gooley T, Applebaum FR, Deeg HJ. Splenectomy and myeloid metaplasia: a hematopoietic stem cell transplantation for myelofibrosis. Blood 2001;97:2180–2181.

224. Silverstein MN. Agnogenic myeloid metaplasia. Acton, Mass: Publishing Science Group; 1975.

225. Rodriguez JN, Martino ML, Dieguez JC, Prados D. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analysis of reports. Haematologica 1998;83:616–621.

226. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Darbeepoetin-alpha for the anemia of myelofibrosis with myeloid metaplasia. Br J Haematol 2006;134:184–186.

227. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Torrebable M, Montserrat E. Erythropoietin treatment of the anemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004;127:399–403.

228. Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000;85:595–599.

229. Cervantes F, Alvarez-Larran A, Domingo A, Arrellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129:771–775.

230. Tefferi A, Elliot MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood 2000;96:4007.

231. Elliot MA, Mesa RA, Li CY, et al. Thalidomide treatment associated with myeloid metaplasia. Br J Haematol 2002;117:288–296.

232. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and spleenomegaly in myelofibrosis with myeloid metaplasia: phase II trial. J Clin Oncol 2004;22:424–431.

233. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 2004;79:883–889.

234. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534–2541.

235. Tefferi A, Lasho TL, Finke C, Hood JD, et al. Primary cell experiments and ongoing clinical trials suggest a role for the Jak2/STAT5 signaling pathway in essential thrombocythemia. Blood 2007;110:5541a.

236. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a Selective Jak2 inhibitor, in treatment of a murine model of Jak2V617F-induced polycythemia vera [abstract]. Blood 2007;110:556a.

237. Geron I, Abrahamsson A, Barroga C, et al. Selective inhibition of Jak2 driven erythropoietin differentiation of polycythemia vera progenitors [abstract]. Blood 2007;110:1556a.

238. Zaleskas VM, Chan WW, Evangelista P, et al. A selective and potent oral inhibitor of the Jak2 tyrosine kinase reverses polycythemia and leukocytosis induced by Jak2 V617F in a mouse model [abstract]. Blood 2007;110:557a.

239. Pardanani A. Jak2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008;22:3–10.

240. Guerin V, Barbui V, Spina C, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated Jak2(V617F). Leukemia 2008;22:740–747.

241. Verostovsk S, Kantarjian H, Pardanani A, et al. INCB018424, an oral, selective Jak2 inhibitor, shows significant clinical activity in a phase I/ii study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV,ET MF) [abstract]. Blood 2007;110:555a.

242. Verostovsk S, Pardanani AD, Shah NP, et al. A Phase I study of XL019, a selective Jak2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis [abstract]. Blood 2007;110:555a.

243. Verostovsk S, Tefferi A, Kornblau S, et al. Phase II study of CEP701, an orally available Jak2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis [abstract]. Blood 2007;110:555a.

244. Verostovsk S, Tefferi A, Kornblau S, et al. Phase II study of CEP701, an orally available Jak2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis [abstract]. Blood 2007;110:555a.

245. Hexner EO, Serdficki C, Jan M, et al. Lestauntinib (CEP701) a Jak2 inhibitor that suppresses Jak2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111:5663–5671.